Newsletter | November 16, 2026

11.16.26 -- Rethinking Commercial Viability In CGT With Treehill Partners' Ali Pashazadeh

SPONSOR

Lentiviral Vector Quality Control

As the application of lentiviral (LV) vectors continues to expand, understanding the critical aspects of biosafety testing and quality control becomes paramount. This webinar explores the latest advancements in release testing of LV vectors, focusing on the key requirements for ensuring patient safety and therapeutic efficacy. You will gain insights into the regulatory landscape for performing release testing, including the detection of RCL and the methodology for determining infectious titer. Watch.

FOCUS ON OUTSOURCING

Rethinking Commercial Viability In CGT With Treehill Partners' Ali Pashazadeh

Episode 141 of Cell & Gene: The Podcast features Host Erin Harris' discussion with Ali Pashazadeh, Founder, Chairman, and CEO of Treehill Partners, about the manufacturing challenges that continue to limit cell and gene therapy development.

Pharma Procurement Playbook: A Guide To Supplier Selection

Stop optimizing for cost alone. Use this cross-functional framework to select reliable CDMOs and API manufacturers that won't fail your pipeline later.

How To Build A Cell Therapy CMC Roadmap

A structured, phase-appropriate regulatory roadmap helps cell therapy developers reduce risk, streamline manufacturing and testing, and avoid costly clinical delays.

The Real Cost Of Poor Data Governance In Advanced Manufacturing

Artificial intelligence is reshaping healthcare. Discover proven strategies for secure, compliant AI adoption, strong data governance, and seamless integration to improve patient outcomes.

A Comprehensive Characterization Of Full, Partial, And Empty Lentiviral Vectors

Confirming that a lentiviral vector is functional means detecting its envelope protein, capsid protein, and RNA payload together, rather than inferring composition from separate assays.

CAR-T Has A Geography Problem

Cellular immunotherapies deliver strong clinical results, but centralized manufacturing and complex logistics limit access. Regional, standardized production can expand global patient access.

Advanced Analytics Required For Bispecific Antibody Quality Control

Bispecific antibody quality control demands advanced analytics to detect mispaired species, assess structural integrity, and confirm potency, ensuring safety and efficacy across diverse therapeutic applications.

OUTSOURCING SOLUTIONS

•

Solving Your Challenges On The Path To Patients - Comprehensive Cell Solutions, A Business Unit of NYBC Enterprises

•

Cell & Gene Therapy Clinical Development Testing - Eurofins

Connect With Cell & Gene: